Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease

Inhaled long-acting bronchodilators, including long-acting β(2) agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are the mainstay therapy in the treatment of chronic obstructive pulmonary disease (COPD), a disease that poses a heavy burden on morbidity and mortality worldwide. Use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Meng-Ting, Lai, Jyun-Heng, Tsai, Chen-Liang, Liou, Jun-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Food and Drug Administration 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307027/
https://www.ncbi.nlm.nih.gov/pubmed/31324282
http://dx.doi.org/10.1016/j.jfda.2018.12.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307027/
https://www.ncbi.nlm.nih.gov/pubmed/31324282
http://dx.doi.org/10.1016/j.jfda.2018.12.006

Ejemplares similares